Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 836

1.

Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury.

Kurokawa T, Tsurita G, Tanimoto T, Yamada T, Ferrone S.

J Clin Oncol. 2018 Jun 29:JCO2018778761. doi: 10.1200/JCO.2018.77.8761. [Epub ahead of print] No abstract available.

PMID:
29958036
2.

Acute and long-lasting cortical thickness changes following intensive first-person action videogame practice.

Momi D, Smeralda C, Sprugnoli G, Ferrone S, Rossi S, Rossi A, Di Lorenzo G, Santarnecchi E.

Behav Brain Res. 2018 Jun 23;353:62-73. doi: 10.1016/j.bbr.2018.06.013. [Epub ahead of print]

PMID:
29944915
3.

Methods for improving the immunogenicity and efficacy of cancer vaccines.

Pilla L, Ferrone S, Maccalli C.

Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17.

PMID:
29874943
4.

Age of Insomnia Onset Correlates with a Reversal of Default Mode Network and Supplementary Motor Cortex Connectivity.

Santarnecchi E, Del Bianco C, Sicilia I, Momi D, Di Lorenzo G, Ferrone S, Sprugnoli G, Rossi S, Rossi A.

Neural Plast. 2018 Apr 1;2018:3678534. doi: 10.1155/2018/3678534. eCollection 2018.

5.

Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73].

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Jun;61:71. doi: 10.1016/j.nucmedbio.2018.03.004. Epub 2018 Apr 25. No abstract available.

PMID:
29705525
6.

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.

Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK.

Photochem Photobiol Sci. 2018 May 16;17(5):539-551. doi: 10.1039/C7PP00358G.

PMID:
29565434
7.

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.

Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Int J Mol Sci. 2018 Mar 21;19(4). pii: E925. doi: 10.3390/ijms19040925.

8.

Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma.

Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL.

J Extracell Vesicles. 2018 Feb 15;7(1):1435138. doi: 10.1080/20013078.2018.1435138. eCollection 2018.

9.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184
10.

Defective HLA class I antigen processing machinery in cancer.

Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S.

Cancer Immunol Immunother. 2018 Jun;67(6):999-1009. doi: 10.1007/s00262-018-2131-2. Epub 2018 Feb 27.

PMID:
29487978
11.

212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Mar;58:67-73. doi: 10.1016/j.nucmedbio.2017.12.004. Epub 2017 Dec 24. Erratum in: Nucl Med Biol. 2018 Apr 25;:.

PMID:
29413459
12.

Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP.

Wang X, Wang X, Gu J, Zhou M, He Z, Wang X, Ferrone S.

Oncotarget. 2017 Dec 6;8(69):113837-113846. doi: 10.18632/oncotarget.22985. eCollection 2017 Dec 26.

13.

HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.

Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Oral Oncol. 2018 Feb;77:92-97. doi: 10.1016/j.oraloncology.2017.12.014. Epub 2017 Dec 28.

PMID:
29362132
14.

Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives.

Marra A, Ferrone CR, Fusciello C, Scognamiglio G, Ferrone S, Pepe S, Perri F, Sabbatino F.

Anticancer Agents Med Chem. 2018;18(2):166-181. doi: 10.2174/1871520618666171219115335.

PMID:
29256359
15.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

16.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
17.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

PMID:
29025772
18.

The Humoral Theory of Transplantation.

Ravindranath MH, Cai J, Ferrone S, Claas FHJ, Selvan SR.

J Immunol Res. 2017;2017:5935123. doi: 10.1155/2017/5935123. Epub 2017 Aug 8. No abstract available.

19.

High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes.

Romoli MR, Di Gennaro P, Gerlini G, Sestini S, Brandani P, Ferrone S, Borgognoni L.

Cell Immunol. 2017 Oct;320:29-37. doi: 10.1016/j.cellimm.2017.08.007. Epub 2017 Aug 30.

PMID:
28870403
20.

A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.

Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X.

Cancer Lett. 2017 Nov 28;409:9-19. doi: 10.1016/j.canlet.2017.08.028. Epub 2017 Aug 30.

21.

ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.

Wang X, Wang Y, Gu J, Zhou D, He Z, Wang X, Ferrone S.

Sci Rep. 2017 Aug 29;7(1):9687. doi: 10.1038/s41598-017-10468-x.

22.

Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers.

Ravindranath MH, Jucaud V, Ferrone S.

J Immunol Methods. 2017 Nov;450:73-80. doi: 10.1016/j.jim.2017.07.016. Epub 2017 Aug 4.

PMID:
28782523
23.

Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Al-Sukaini A, Hornicek FJ, Peacock ZS, Kaban LB, Ferrone S, Schwab JH.

Clin Orthop Relat Res. 2017 Dec;475(12):3071-3081. doi: 10.1007/s11999-017-5451-1. Epub 2017 Jul 19.

PMID:
28725958
24.

Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.

Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, Clardy S, Huang CH, Pille C, Ferrone S, Yang R, Castro CM, Lee H, Del Castillo CF, Weissleder R.

Sci Transl Med. 2017 May 24;9(391). pii: eaal3226. doi: 10.1126/scitranslmed.aal3226.

25.

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC.

Sci Rep. 2017 May 23;7(1):2290. doi: 10.1038/s41598-017-02608-0.

26.

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.

Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G.

Front Immunol. 2017 Apr 27;8:457. doi: 10.3389/fimmu.2017.00457. eCollection 2017. Review.

27.

Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.

Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X.

Oncotarget. 2017 Jun 6;8(23):37646-37656. doi: 10.18632/oncotarget.16841.

28.

HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Seliger B, Kloor M, Ferrone S.

Oncoimmunology. 2017 Feb 6;6(2):e1171447. doi: 10.1080/2162402X.2016.1171447. eCollection 2017. Review.

29.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.

Maccalli C, Parmiani G, Ferrone S.

Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13. Review.

PMID:
28287848
30.

B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.

31.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

32.

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.

Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL.

Clin Cancer Res. 2016 Nov 1;22(21):5229-5237. Epub 2016 May 23.

33.

AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.

Conteduca G, Fenoglio D, Parodi A, Battaglia F, Kalli F, Negrini S, Tardito S, Ferrera F, Salis A, Millo E, Pasquale G, Barra G, Damonte G, Indiveri F, Ferrone S, Filaci G.

Oncotarget. 2016 Sep 20;7(38):60872-60884. doi: 10.18632/oncotarget.11506.

34.

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.

Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL.

Clin Cancer Res. 2017 Feb 1;23(3):707-716. doi: 10.1158/1078-0432.CCR-16-0879. Epub 2016 Aug 5.

35.

Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL.

Oral Oncol. 2016 Jul;58:52-8. doi: 10.1016/j.oraloncology.2016.05.008. Epub 2016 Jun 2. Review.

36.

Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.

Piras LA, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P.

Vet Comp Oncol. 2017 Sep;15(3):996-1013. doi: 10.1111/vco.12239. Epub 2016 May 4.

37.

Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.

Villani V, Mahadevan KK, Ligorio M, Fernández-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):609-617. Epub 2016 Mar 28.

PMID:
27020585
38.

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180.

39.

Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.

Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S.

J Natl Cancer Inst. 2016 Feb 5;108(7). doi: 10.1093/jnci/djv435. Print 2016 Jul.

40.

CSPG4 as a prognostic biomarker in chordoma.

Schoenfeld AJ, Wang X, Wang Y, Hornicek FJ, Nielsen GP, Duan Z, Ferrone S, Schwab JH.

Spine J. 2016 Jun;16(6):722-7. doi: 10.1016/j.spinee.2015.11.059. Epub 2015 Dec 9.

PMID:
26689475
41.

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage.

Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G.

Oncotarget. 2016 Jan 12;7(2):2070-9. doi: 10.18632/oncotarget.6529.

42.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

43.

Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Wang Y, Wang X, Ferrone CR, Schwab JH, Ferrone S.

Mol Oncol. 2015 Dec;9(10):1982-93. doi: 10.1016/j.molonc.2015.10.019. Epub 2015 Oct 30. Review.

44.

HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.

Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E.

Eur J Immunol. 2016 Feb;46(2):409-19. doi: 10.1002/eji.201445289. Epub 2015 Dec 20.

45.

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Tsao CY, Sabbatino F, Cheung NK, Hsu JC, Villani V, Wang X, Ferrone S.

Oncoimmunology. 2015 Apr 2;4(8):e1023975. eCollection 2015 Aug.

46.

Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S.

J Biol Chem. 2015 Oct 30;290(44):26562-75. doi: 10.1074/jbc.M115.676130. Epub 2015 Sep 17.

47.

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.

Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR.

Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.

48.

Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.

Wang Y, Geldres C, Ferrone S, Dotti G.

Expert Opin Ther Targets. 2015;19(10):1339-50. doi: 10.1517/14728222.2015.1068759. Epub 2015 Jul 18. Review.

PMID:
26190756
49.

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF 4th, Ferrone S, Ferris RL.

Cancer Immunol Res. 2015 Aug;3(8):936-45. doi: 10.1158/2326-6066.CIR-15-0053. Epub 2015 May 13.

50.

CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL.

Cancer Res. 2015 Jun 1;75(11):2200-10. doi: 10.1158/0008-5472.CAN-14-2788. Epub 2015 Apr 1.

Supplemental Content

Loading ...
Support Center